Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 11. Summary of Survival in Second-line (or Higher) Treatment With Cytotoxic Chemotherapy for Advanced NSCLC

Study ID Diagnosis
(no. of patients)
Sub-groups Survival from Start of Treatment Progression-free Survival
Median (months) 1-year
(%)
HR (95% CI)
[p-value]
Median TTP
(months)
1-year
(%)
HR (95% CI)
[p-value]
Phase III
Shepherd, et al., 200033 NSCLC
(204)
BSC
Docetaxel 75 mg/m2
Docetaxel 100 mg/m2
4.6
7.5
5.9
- -
- -
- -
 
p = 0.010
p = 0.047
- -
- -
- -
- -
- -
- -
 
- -
- -
Fossella, et al., 200034 NSCLC
(358)
Vinorelbine 30 mg/m2 or
ifosfamide 2 mg/m2
Docetaxel 75 mg/m2
Docetaxel 100 mg/m2
5.4

5.8
6.6
10

32
32


p = 0.001
p = 0.002
7.9 b

8.5 b
8.4 b
- -

- -
- -
 

p = 0.093
p = 0.046
Hanna, et al., 200432 NSCLC
(571)
Pemetrexed 500 mg/m2
Docetaxel 75 mg/m2
8.3
7.9
30
30
0.99 2.9
2.9
- -
- -
0.97
[p = 0.76]
Retrospective
Massarelli, et al., 200335 NSCLC
43 pts
14 pts
Various regimens
3rd line
4th line
 
5.4
5.9
 
- -
- -
 
- -
- -
 
- -
- -
 
- -
- -
 
- -

b Fossella, et al., (2000)34 reported time to progression (TTP) in patients who were censored at the time of administration of subsequent therapy, which is why the TTP is longer than median survival.

Abbreviations: BSC = best supportive care; CI = confidence interval; HR = hazard ratio; no. = number; NR = not reported; NSCLS = non-small cell lung cancer; TTP = time to progression.

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care